Lawmakers Push Medicare Coverage for Early Alzheimer's Blood Tests

Sens. Kevin Cramer and Susan Collins and Rep. Nanette Barragán back the ASAP Act to cover FDA-approved early detection tests.

Updated on Nov. 18, 2026 in Alzheimer’s

Lawmakers Push Medicare Coverage for Early Alzheimer's Blood Tests

Live Poll

Should Medicare cover early blood tests for Alzheimer's and other dementias?

Sen. Kevin Cramer (R-N.D.) and Rep. Nanette Barragán (D-Calif.) are advocating for passage of the Alzheimer's Screening and Prevention (ASAP) Act. The bill, introduced last year by Sen. Susan Collins (R-Maine), would authorize the Centers for Medicare and Medicaid Services to cover FDA-approved early detection blood tests under Medicare.

Why it matters

Early diagnosis is better for treatment, preparation, and possible cures, according to the lawmakers' arguments. Early screening may also reduce long-term costs tied to nursing and in-home care for people with dementia.

The ASAP Act would authorize Medicare coverage of FDA-approved early detection blood tests, including newly approved tests. The extraction does not report the bill's projected cost or the number of Americans affected.

The players

Sen. Kevin Cramer

Cramer is a Republican senator from North Dakota who is advocating for the ASAP Act.

Rep. Nanette Barragán

Barragán is a Democratic congresswoman from California who is advocating for the ASAP Act.

Sen. Susan Collins

Collins is a Republican senator from Maine who introduced the ASAP Act last year.

Centers for Medicare and Medicaid Services (CMS)

CMS is the federal agency that administers Medicare and would be authorized to cover the approved blood tests under the bill.

The details

At a Wednesday event hosted by The Hill and sponsored by HealthyWomen, Cramer and Barragán discussed the legislation. Both lawmakers said their mothers had Alzheimer's, and the bill would also authorize Medicare coverage for new blood tests as they receive FDA approval.

Timeline

  1. Last year: Sen. Susan Collins introduced the ASAP Act.

  2. Wednesday, November 18, 2026: Lawmakers pushed for the bill at a Washington, D.C. event hosted by The Hill.

Roadmap

The ASAP Act would extend Medicare's existing authority to cover FDA-approved diagnostics to early Alzheimer's blood tests, rather than creating a new program. It would also cover future FDA-approved blood tests, placing the bill within a broader push to tie federal reimbursement to approved diagnostic technology.

If the ASAP Act passes, Medicare beneficiaries could access FDA-approved early detection blood tests for Alzheimer's and other dementias. The extraction does not state when coverage would begin or what out-of-pocket costs patients would face.

The takeaway

Early detection of Alzheimer's could allow for earlier treatment planning, and Medicare coverage for FDA-approved blood tests would make that screening available to more people if the ASAP Act is enacted.

Further reading

For more on the disease itself, see the Alzheimer's section.

Source note: This article includes information reported by The Hill.

Live Poll

Should Medicare cover early blood tests for Alzheimer's and other dementias?